Microarray News and Research

RSS

Ingenuity Systems appoints SeouLin Bioscience as exclusive distributor of IPA software in South Korea

Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced the appointment of SeouLin Bioscience Co., Ltd. as the exclusive distributor of IPA in South Korea.

25 Jan 2010

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.

24 Jan 2010

Kalorama report predicts double-digit growth in SNP market

A setback in the scientific basis for SNP (single nucleotide polymorphisms) analysis may turn out to be a blessing in disguise for makers of genotyping equipment, reagents and software, according to Kalorama Information.

23 Jan 2010

Combination of saliva test with ultra high-tech biopsy process may help prevent genetic disorders

Florida's largest fertility clinic announced it is the first in the state to offer promising new tests against birth defects: a coupling of technologies that will allow couples to avoid passing along more than 100 genetic diseases to their newborn.

22 Jan 2010

QuantRx Biomedical's developments in genetics-based technology

QuantRx® Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today provided an update from Chairman and Chief Executive Officer Walter Witoshkin on its involvement in genetics-based personalized medicine and disease prevention.

20 Jan 2010

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth.

20 Jan 2010

Treatment for metastatic tumor based on its unique protein makeup

Imagine if treatments for disease could be based not on a patient's diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) today jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

7 Jan 2010

Arrayit achieves technological breakthrough in microarray production

Arrayit Corporation, a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics.

22 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Landmark study provides new insight into congenital heart defects

Researchers from the UC San Diego, School of Medicine and colleagues have identified a new gene, ETS-1, that is linked to human congenital heart defects. The landmark study, recently published online in the journal of Human Molecular Genetics, provides important insights into some of the most prevalent forms of congenital heart defects in humans, including ventricular septal defects and potentially hypoplastic left heart syndrome, a uniformly fatal heart abnormality.

18 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009

Eppendorf initiates import ban against Nanosphere's Verigene and Verigene SP systems

Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

16 Dec 2009

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Roche NimbleGen has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program.

16 Dec 2009

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today announced that it has signed an exclusive License Agreement with Wayne State University to key intellectual property covering discoveries of biomarkers of ovarian cancer.

10 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, selected febit's Geniom® RT Analyzer to advance its biomedical research by proceeding targeted Next-Generation Sequencing (NGS), genome-wide single nucleotide polymorphism (SNP) and microRNA (miRNA) analysis.

2 Dec 2009

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH).

1 Dec 2009

Microarray News and Research

Ingenuity Systems appoints SeouLin Bioscience as exclusive distributor of IPA software in South Korea

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Kalorama report predicts double-digit growth in SNP market

Combination of saliva test with ultra high-tech biopsy process may help prevent genetic disorders

QuantRx Biomedical's developments in genetics-based technology

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Treatment for metastatic tumor based on its unique protein makeup

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

Arrayit achieves technological breakthrough in microarray production

TessArae's RM-Flu test granted FDA EUA

Landmark study provides new insight into congenital heart defects

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

Eppendorf initiates import ban against Nanosphere's Verigene and Verigene SP systems

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics